Reed Jobs launched the oncology-focused venture firm Yosemite in 2023, aiming to create biotech companies from academic research. The firm is expanding its focus, integrating AI into drug discovery and clinical trial design amidst a wave of new opportunities following patent expirations for existing drugs.
Reed Jobs, son of Steve Jobs, is focusing on his work with Yosemite, a venture firm he founded in 2023. Rather than discussing his legacy, Jobs emphasizes his passion for oncology and advancing cancer treatments through innovative approaches.
Yosemite differentiates itself by exclusively working in oncology, aiming to construct companies from scratch using early-stage academic research. Jobs believes the future of cancer treatment is not within existing pharmaceutical companies but rather in new innovations arising from universities.
With the rapid advancement of artificial intelligence, Yosemite has begun integrating AI into its drug discovery process and clinical trial design. This shift reflects the growing significance of AI in the biotech industry and the opportunities it presents for developing new therapies.
Yosemite has grown to a team of 17 and is actively engaged in various projects, including notable startups like Azalea and Quarry. The firm is targeting a second fund of $350 million, demonstrating substantial traction and interest in its mission.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
Reed Jobs launched the oncology-focused venture firm Yosemite in 2023, aiming to create biotech companies from academic research. The firm is expanding its focus, integrating AI into drug discovery and clinical trial design amidst a wave of new opportunities following patent expirations for existing drugs.